aspirin has been researched along with sirolimus in 130 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.54) | 18.2507 |
| 2000's | 54 (41.54) | 29.6817 |
| 2010's | 67 (51.54) | 24.3611 |
| 2020's | 7 (5.38) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cai, W; Foulkes, JG; Hu, L | 1 |
| Ciccarelli, A; de Crescenzo, G; de Paulis, A; Marinò, D; Marinò, I; Marone, G | 1 |
| Acampado, E; Farb, A; John, M; Kolodgie, FD; Prescott, MF; Virmani, R | 1 |
| Albiero, R; Colombo, A; Corvaja, N; Di Mario, C; Falotico, R; Stankovic, G; Takagi, T; Toutouzas, K | 1 |
| Colombo, A; Desmedt, B; Di Mario, C; Holmes, DR; Leon, MB; Louvard, Y; Ludwig, J; Morice, MC; Moses, JW; Spanos, V | 1 |
| Bachinsky, W; Bass, T; DeMaio, S; Fry, E; Holmes, DR; Kuntz, RE; Leon, MB; Moses, JW; Popma, JJ; Sawhney, N; Teirstein, PS | 1 |
| Cox, N; Douglas, J; Fitzpatrick, M; Holmes, DR; Kuntz, RE; Lambert, C; Leon, MB; Mooney, M; Moses, JW; Popma, JJ; Yakubov, S | 1 |
| Karvouni, E; Katritsis, DG; Korovesis, S | 1 |
| Claussen, CD; Dinkelborg, LM; Duda, SH; Laule, M; Muschick, P; Reddig, F; Tepe, G; Tielemans, H; Wehrmann, M | 1 |
| Marotta, PJ; McAlister, VC; Skaro, AI | 1 |
| Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W | 1 |
| Fitzsimmons, P; Mixon, T | 1 |
| Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J | 1 |
| Dehmer, GJ; McAllister, RK; Meyer, TA | 1 |
| Aslani, A; Sharifkazemi, MB; Zamirian, M | 1 |
| Hirata, K; Matsumoto, D; Ogasawara, D; Otake, H; Paredes, OL; Sawada, T; Shinke, T; Shite, J; Tanino, Y; Yokoyama, M | 1 |
| Grinius, V; Navickas, R; Unikas, R | 1 |
| Holmes, DR; Kuntz, RE; Leon, MB; Mishkel, G; Moses, JW; Popma, JJ; Raizner, AE; Satler, LF; Teirstein, PS; Wang, P; Weisz, G; Wilensky, RL | 1 |
| Finn, AV; Gold, HK; John, MC; Joner, M; Kolodgie, F; Nakazawa, G; Newell, J; Virmani, R | 1 |
| Khurana, A; Vinayek, N | 1 |
| LeLorier, J; Matteau, A | 1 |
| Aubry, P; Benamer, H; Ducrocq, G; Feldman, LJ; Himbert, D; Juliard, JM; Majdoub, MA; Sauguet, A; Steg, PG; Tchetche, D | 1 |
| Alfonso, F; Angiolillo, DJ; Bañuelos, C; Escaned, J; Fernández, C; Fernández-Avilés, F; Gómez-Hospital, JA; Hernández-Antolín, R; Jiménez-Quevedo, P; Macaya, C; Moreno, R; Sabaté, M; SanMartín, M | 1 |
| Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E | 1 |
| Spinler, SA; Wilensky, RL | 1 |
| Arab, D; Cohoon, K; Dieter, RS; Freihage, JH; Joyal, D; Lewis, B; Leya, F; Steen, L; Tempelhof, M | 1 |
| Airoldi, F; Bonizzoni, E; Briguori, C; Buellesfeld, L; Carlino, M; Chieffo, A; Colombo, A; Cosgrave, J; Gerckens, U; Godino, C; Grube, E; Latib, A; Melzi, G; Michev, I; Montorfano, M; Morici, N; Qasim, A; Sangiorgi, GM | 1 |
| Bavry, AA; Bhatt, DL | 1 |
| Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC | 1 |
| Fujimoto, Y; Himi, T; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Miyazaki, A; Nakamura, Y; Nakayama, T | 1 |
| Batyraliev, TA; Pershukov, IV | 1 |
| Atsma, DE; Bootsma, M; Dijkstra, J; Jukema, JW; Liem, SS; Oemrawsingh, PV; Putter, H; Schalij, MJ; Suraphakdee, N; van der Hoeven, BL; van der Wall, EE; Zeppenfeld, K | 1 |
| Haase, J; Ruef, J; Schwarz, F; Störger, H | 1 |
| Biondi-Zoccai, GG; Bollati, M; Gambino, A; Lombardi, P; Sheiban, I | 1 |
| Eshtehardi, P; Eslami, M; Moayed, DA | 1 |
| Hagioka, S; Kasai, S; Komatsubara, I; Kubo, Y; Matsumoto, M; Morimoto, N; Nagae, M; Naito, H; Onoue, G; Seito, T; Shiraishi, K; Suehiro, K | 1 |
| Chen, X; Gao, R; Han, Y; Jing, Q; Li, Y; Liu, H; Luan, B; Ma, Y; Wang, D; Wang, G; Wang, S; Wang, Z; Xu, B | 1 |
| Asakura, Y; Ehara, M; Katoh, O; Kimura, M; Kinoshita, Y; Matsubara, T; Nasu, K; Suzuki, T; Tanaka, N; Terashima, M; Tsuchikane, E | 1 |
| Chen, JL; Gao, RL; Hu, J; Qiao, SB; Qin, XW; Shen, WF; Xu, B; Yang, YJ; Zhang, JS; Zhang, Q; Zhang, RY | 1 |
| Airoldi, F; Bedogni, F; Bonizzoni, E; Brambilla, N; Briguori, C; Carlino, M; Chieffo, A; Colombo, A; Cosgrave, J; Godino, C; Latib, A; Montorfano, M; Morici, N; Sangiorgi, GM | 1 |
| Burtt, D; Chodosh, A; Korr, KS | 1 |
| Cho, EJ; Her, SH; Jang, SW; Kim, DB; Kim, JH; Kwon, BJ; Park, CS; Park, HJ; Park, MW; Rho, TH; Shin, D | 1 |
| Dean, J; Wanjun, C; Yingxin, Z; Yonghe, G; Yujie, Z; Yuyang, L; Zheng, C | 1 |
| Ikari, Y; Kotani, J; Kozuma, K; Kyo, E; Nakamura, M; Yokoi, H | 1 |
| Hartenthaler, B; Hofmann, R; Hönig, S; Kammler, J; Kerschner, K; Kypta, A; Lambert, T; Leisch, F; Steinwender, C | 1 |
| Angiolillo, DJ; Brugaletta, S; Campos, B; Cola, C; Martín Yuste, V; Sabaté, M | 1 |
| Abizaid, A; Bonan, R; Costa, JR; Costa, R; Feres, F; Mattos, LA; Siqueira, D; Sousa, AG; Sousa, JE; Staico, R; Tanajura, LF | 1 |
| Peters-Krabbendam, I; Serruys, PW; Sorop, O; van Beusekom, HM; van der Giessen, WJ | 1 |
| Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H | 1 |
| Margolis, JR | 1 |
| Abizaid, A; Bonan, R; Costa, JR; Costa, R; Feres, F; Maldonado, G; Siqueira, D; Sousa, AG; Sousa, JE; Staico, R; Tanajura, LF | 1 |
| Ako, J; Fitzgerald, PJ; Hirata, K; Honda, Y; Kato, H; Koo, BK; Miyoshi, N; Ogasawara, D; Otake, H; Sawada, T; Shinke, T; Shite, J; Tanino, Y | 1 |
| Akishita, M; Ako, J; Eto, M; Iijima, K; Ogawa, S; Ota, H; Ouchi, Y | 1 |
| Chen, M; Huang, DJ; Huang, KS; Wu, Q | 1 |
| Ding, FH; DU, R; Hu, J; Shen, J; Shen, WF; Zhang, Q; Zhang, RY; Zhang, X; Zhao, LP | 1 |
| Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC | 1 |
| Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C | 1 |
| Balbi, M; Barsotti, A; Bezante, GP; Brunelli, C; Fedele, M | 1 |
| Shen, WF | 1 |
| Al-Dehneh, A; Alkhouri, Y; Bikkina, M; Hamdan, A; Virk, H | 1 |
| Cho, BR; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Han, KR; Hur, SH; Lee, S; Lee, SH; Lee, SY; Lim, DS; Park, HS; Park, JS; Rha, SW; Song, YB; Yoon, J | 1 |
| Ikari, Y; Katsuta, Y; Kotani, J; Kozuma, K; Kyo, E; Nagai, Y; Nakamura, M; Nozaki, E; Onodera, T; Ota, Y; Yokoi, H | 1 |
| Esser, J; Gabrielsson, S; Gehrmann, U; Haeggström, JZ; Rådmark, O; Salvado, MD; Samuelsson, B; Scheynius, A; Wetterholm, A | 1 |
| Caixeta, A; Gordon, P; Hermiller, JB; Jonnavithula, L; Lansky, AJ; Miquel-Hebert, K; Onuma, Y; Ruygrok, P; Serruys, PW; Sood, P; Stone, GW; Su, X; Sudhir, K; Veldhof, S; Yaqub, M | 1 |
| Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K | 1 |
| Fearon, WF; Hunt, SA; Ikeno, F; Lee, DP; Ng, MK; Tremmel, JA; Yeung, AC | 1 |
| Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S | 1 |
| Blackman, DJ; Blaxill, JM; Chitkara, K; Dorsch, MF; Greenwood, JP; McLenachan, JM; Shelton, RJ; Singh, R; Somers, K; Wheatcroft, SB | 1 |
| Barker, CS; Fajadet, J; Kandzari, DE; Leon, MB; Mauri, L; Mehran, R; Wijns, W | 1 |
| Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P | 1 |
| Renzulli, A; Rossi, M; Serraino, GF; Spadafora, A | 1 |
| Devlin, G; Hyde, L; Liang, M; Liew, TV; Puri, A | 1 |
| Ferraro, G; Gaita, F; Marcolongo, M; Moretti, C; Sheiban, I; Truffa, A | 1 |
| Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G | 1 |
| Witzenbichler, B | 1 |
| Chevalier, B; Diletti, R; Dorange, C; Farooq, V; Garcia-Garcia, HM; Miquel-Hebert, K; Onuma, Y; Rapoza, R; Serruys, PW; Sudhir, K; Veldhof, S | 1 |
| Gao, RL; Han, YL; Jiang, TM; Jing, QM; Li, SM; Li, WM; Li, Y; Liu, HL; Qu, P; Xu, B; Yang, LX; Zhang, L; Zhang, QY | 1 |
| Abizaid, A; Bhatt, DL; Botelho, RV; Castello, H; Costa, RA; de Paula, JE; Devito, FS; Feres, F; Gusmão, MO; King, SB; Leon, MB; Mangione, JA; Marin-Neto, JA; Nicolela, E; Perin, MA; Salvadori, D | 1 |
| Abbott, JD; Faxon, D; Holper, E; Kelsey, S; Khandhar, S; Kip, KE; Kutcher, M; Lee, JS; Marroquin, OC; Mulukutla, SR; Selzer, F; Smith, C; Toma, C; Vlachos, HA; Williams, DO | 1 |
| Darzynkiewicz, Z; Halicka, HD; Hsieh, TC; Lee, YS; Li, J; Wu, JM; Zhao, H | 1 |
| Aarøe, J; Bøtker, HE; Christiansen, EH; Hansen, KN; Jensen, LO; Kaltoft, A; Kristensen, SD; Krusell, LR; Lassen, JF; Madsen, M; Maeng, M; Ravkilde, J; Terkelsen, CJ; Thayssen, P; Thuesen, L; Tilsted, HH; Villadsen, AB | 1 |
| den Heijer, P; Goy, JJ; Hofma, S; Nouche, RT; Serra, A; Slagboom, T; Smits, PC; Togni, M; Valdés, M; van der Ent, M; Vázquez, N; Voudris, V; Vuillomenet, A | 1 |
| Chen, F; Gao, Y; He, J; Luo, Y; Lv, S; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y | 1 |
| McClean, D; Puri, A; Saireddy, R | 1 |
| Chen, F; Chen, SL; Cheng, JP; Kan, J; Lin, L; Liu, LY; Liu, Y; Xu, HM; Zhao, YY | 1 |
| Ikari, Y; Kotani, J; Kyo, E; Nakamura, M; Yokoi, H | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Huang, KN | 1 |
| Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R | 1 |
| Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S | 1 |
| Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W | 1 |
| Alfonso Manterola, F; Doncel Vecino, LJ; Fernández Díaz, JA; Fernández Portales, J; González Fernández, R; López Mínguez, JR; Martínez Cáceres, G; Martínez Romero, P; Merchán Herrera, A; Nogales Asensio, JM; Romany, S; Sandoval, J | 1 |
| Fischman, DL; Jasti, B; Kaliyadan, A; Ogilby, JD; Ruggiero, NJ; Savage, MP; Siu, H; Walinsky, P | 1 |
| Alber, H; Buser, P; Conen, D; Eberli, F; Galatius, S; Gilgen, N; Hoffmann, A; Jeger, R; Kaiser, C; Kurz, DJ; Moccetti, T; Müller, C; Naber, C; Pedrazzini, G; Pfisterer, M; Rickenbacher, P; Rickli, H; Skov Jensen, J; Steiner, M; Vogt, DR; Von Felten, S; Vuillomenet, A; Wadt Hansen, K; Wanitschek, M; Weilenmann, D | 1 |
| Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S | 1 |
| Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J | 1 |
| Blagosklonny, MV | 1 |
| Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW | 1 |
| Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R | 1 |
| Airoldi, F; Briguori, C; Campo, G; Colangelo, S; de Cesare, N; Dellavalle, A; Ferlini, M; Gabriel, HM; Garbo, R; Liistro, F; McFadden, E; Meliga, E; Menozzi, A; Patialiakas, A; Roffi, M; Tebaldi, M; Testa, L; Thury, A; Tondi, S; Ungi, I; Valgimigli, M; Vranckx, P | 1 |
| Guo, XF; Han, YL; Li, B; Liu, Q; Lu, SZ; Pang, S; Su, X; Xu, B; Yang, YJ; Zhang, YJ; Zhao, YL | 1 |
| Akasaka, T; Hanawa, K; Hao, K; Hasebe, Y; Hirano, M; Ito, K; Matsumoto, Y; Miyata, S; Nishimiya, K; Ogata, T; Oyama, K; Shimokawa, H; Shindo, T; Takahashi, J; Tanaka, A; Taruya, A; Tsuburaya, R; Uzuka, H | 1 |
| Dohi, K; Fujimoto, N; Fukuoka, S; Ito, M; Izumi, D; Miyahara, M; Sakai, M | 1 |
| Golshayan, D; Kumar, R; Pascual, M; Roehrich, ME; Vassalli, G; Wyss, JC | 1 |
| Chang, K; Choi, YS; Chung, WB; Chung, WS; Kim, HY; Kim, JY; Kwon, A; Lee, MY; Park, CS; Seung, KB | 1 |
| Garcia-Garcia, HM; Hamm, C; Jüni, P; Serruys, PW; Steg, PG; Valgimigli, M; van Es, GA; Vranckx, P; Windecker, S | 1 |
| Ahn, DJ; Han, DK; Joung, YK; Jung, JW; Lih, E | 1 |
| Cao, X; Dangas, GD; Guan, C; Han, Y; Jing, Q; Li, J; Li, X; Pang, W; Wang, H; Wang, Z; Xu, B; Xu, K; Yang, Y; Yu, P; Zang, H; Zhang, J; Zhao, X; Zheng, Q | 1 |
| Abdul, F; Anderson, R; Butt, M; Chase, A; Choudhury, A; Gallagher, S; Hailan, A; Kinnaird, T; Ossei-Gerning, N; Smith, D; Yazji, K | 1 |
| Choi, D; Hong, MK; Jang, Y; Kim, BK; Kim, HS; Kim, JS; Ko, YG; Lee, SY; Palmerini, T; Shin, DH; Stone, GW; Valgimigli, M | 1 |
| Cho, DK; Choi, JH; Choi, SH; Doh, JH; Gwon, HC; Hahn, JY; Kim, SH; Lee, JB; Lee, JM; Lee, SH; Oh, JH; Park, TK; Song, YB; Yang, JH | 1 |
| Abizaid, A; Costa, JR; Costa, R; Feres, F; Mangione, JA; Piva E Mattos, LA; Siqueira, D; Sousa, A; Staico, R; Zuliani Mauro, MF | 1 |
| Hayashi, K; Kawashiri, MA; Mori, M; Nakahashi, T; Nakanishi, C; Okada, H; Sakata, K; Shimojima, M; Takuwa, Y; Yamagishi, M; Yokawa, JI; Yoshida, S; Yoshimuta, T; Yoshioka, K | 1 |
| Amano, H; Fuku, Y; Goto, T; Habara, S; Kadota, K; Kubo, S; Otsuru, S; Tada, T; Tanaka, H | 1 |
| Cho, DK; Choi, S; Hong, BK; Hong, MK; Jang, Y; Jeon, DW; Kang, TS; Kang, WC; Kim, BK; Kim, BO; Kim, JS; Kim, S; Kim, YH; Kwon, HM; Lee, BK; Lee, OH; Min, PK; Shin, DH; Woo, SI; Yoon, YW | 1 |
| Bailey, LC; Balamuth, NJ; MacFarland, SP; Olson, TS; States, LJ; Sullivan, LM; Womer, RB | 1 |
| Fujimoto, W; Kawai, H; Miyata, T; Oishi, S; Onishi, T; Osue, T; Sawada, T; Shimane, A; Takahashi, Y; Takaya, T; Taniguchi, Y; Toba, T; Yasaka, Y | 1 |
| Ako, J; Ando, K; Anzai, H; Fujii, K; Hamasaki, T; Iijima, R; Inoue, K; Inoue, T; Ishiwata, S; Ito, Y; Kadotani, M; Kataoka, T; Kawaguchi, K; Kawata, M; Kinutani, H; Kuroda, K; Morita, T; Nakamura, M; Niinuma, H; Nishida, Y; Ochiai, M; Ohira, H; Okada, H; Omiya, K; Otake, H; Shinke, T; Takiuchi, S; Tanaka, H; Ueda, Y; Urasawa, K; Yasaka, Y; Yokoi, H; Yoshiyama, M; Zen, K | 1 |
| López-Gutiérrez, JC; Sánchez-Carpintero, I; Triana Junco, PE | 1 |
| Abizaid, A; Brar, S; Kandzari, D; Kedhi, E; Kirtane, AJ; Latib, A; Liu, M; Mehran, R; Price, MJ; Simon, D; Stone, GW; Windecker, S; Worthley, S; Zaman, A | 1 |
| Cao, R; Dai, Y; Ge, J; Li, C; Qian, J; Yang, H; Yang, J; Yao, K; Zhang, F; Zheng, M | 1 |
| Anderson, R; Chang, CC; Chichareon, P; Chowdhary, S; Fath-Ordoubadi, F; Galasko, G; Garg, S; Hamm, CW; Hoole, S; Jüni, P; Kogame, N; Kukreja, N; Modolo, R; Oldroyd, KG; Onuma, Y; Serruys, PW; Stables, RH; Steg, PG; Takahashi, K; Tomaniak, M; Valgimigli, M; Windecker, S; Zaman, A | 1 |
| Burke, CA; Chick, RC; Cindass, JL; Clifton, GT; Ensley, DC; Hale, DF; Hickerson, AT; Kemp Bohan, PM; Mankaney, G; Peoples, GE; Sohn, V; Vreeland, TJ | 1 |
| Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH | 1 |
| Liu, ZY; Meng, WX; Sun, B; Xu, Y; Yang, H | 1 |
| Ako, J; Hibi, K; Hioki, H; Hirohata, A; Ikari, Y; Ito, Y; Kinoshita, Y; Kozuma, K; Morino, Y; Nakagawa, Y; Nanasato, M; Shiode, N; Sonoda, S; Tanabe, K; Yamaguchi, J | 1 |
| Bae, JW; Cho, BR; Cho, DK; Cho, JH; Choi, JH; Choi, JW; Choi, SH; Choi, WG; Chun, WJ; Gwon, HC; Hahn, JY; Im, ES; Jang, WJ; Jeong, JO; Koh, YY; Lee, JM; Lee, JY; Lee, SH; Lee, SU; Lee, SY; Lee, WS; Oh, JH; Oh, SK; Park, TK; Park, YH; Rha, SW; Song, YB; Yang, JH; Yoon, HJ; Yun, KH | 1 |
| Blake, T; Lobo, Y; Wheller, L | 1 |
14 review(s) available for aspirin and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Transcription-modulating drugs: mechanism and selectivity.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Cyclosporine; Drug Design; Estrogen Antagonists; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Polyenes; Sirolimus; Tacrolimus; Thiazoles; Transcription, Genetic | 1996 |
Sirolimus-eluting stents: a review of experimental and clinical findings.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Disease Models, Animal; Drug Delivery Systems; Follow-Up Studies; Humans; Immunosuppressive Agents; Injections, Intramuscular; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Rats; Sirolimus; Stents; Swine; Thrombosis; Ticlopidine; Time Factors; Ultrasonography, Interventional | 2002 |
[Stents in interventional cardiology].
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Diabetes Complications; Drug Delivery Systems; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Humans; Immunosuppressive Agents; Middle Aged; Platelet Aggregation Inhibitors; Prednisolone; Randomized Controlled Trials as Topic; Risk Factors; Sirolimus; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2007 |
[Drug-eluting stent thrombosis and its pharmacological prevention].
Topics: Aspirin; Clopidogrel; Death, Sudden, Cardiac; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Incidence; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Terminology as Topic; Thrombosis; Ticlopidine; Turkey | 2007 |
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Female; Humans; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Sirolimus; Ticlopidine; Treatment Outcome | 2009 |
Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug-Eluting Stents; Electrocardiography; Humans; Male; Middle Aged; Neurosurgical Procedures; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Benchmarking; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Evidence-Based Medicine; Female; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Prosthesis Design; Risk Assessment; Risk Factors; Sirolimus; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Late and very late stent thrombosis in patients with second-generation drug-eluting stents.
Topics: Aspirin; Cardiotonic Agents; Clopidogrel; Drug-Eluting Stents; Everolimus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Thrombosis; Ticlopidine; Time Factors | 2013 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, Sudden, Cardiac; Drug-Eluting Stents; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Failure; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome; Withholding Treatment | 2014 |
Koschei the immortal and anti-aging drugs.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Caloric Restriction; Exercise; Folklore; Gene Expression; Glucose; Humans; Insulin Resistance; Longevity; Metformin; Propranolol; Russia; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Preventive treatment with oral sirolimus and aspirin in a newborn with severe Sturge-Weber syndrome.
Topics: Administration, Oral; Aspirin; Drug Therapy, Combination; Electroencephalography; Humans; Infant, Newborn; Infant, Premature; Lasers, Dye; Magnetic Resonance Imaging; Male; Port-Wine Stain; Primary Prevention; Prognosis; Risk Assessment; Seizures; Severity of Illness Index; Sirolimus; Sturge-Weber Syndrome; Treatment Outcome | 2019 |
Chemoprevention in familial adenomatous polyposis: past, present and future.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Ascorbic Acid; Aspirin; Capsules; Celecoxib; Chemoprevention; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Eflornithine; Erlotinib Hydrochloride; Fatty Acids, Nonesterified; Genes, APC; Humans; Sirolimus; Sulindac; TOR Serine-Threonine Kinases; Vitamins | 2021 |
Management of multiple trichoepithelioma: A review of pharmacological therapies.
Topics: Adalimumab; Administration, Topical; Anilides; Antineoplastic Agents; Aspirin; Humans; Imiquimod; Lasers, Gas; Neoplasms, Adnexal and Skin Appendage; Pyridines; Sirolimus; Skin Neoplasms; Tretinoin | 2021 |
34 trial(s) available for aspirin and sirolimus
| Article | Year |
|---|---|
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Death, Sudden; Diabetes Mellitus; Disease-Free Survival; Drug Implants; Female; Follow-Up Studies; Humans; Life Tables; Male; Middle Aged; Pilot Projects; Postoperative Complications; Prospective Studies; Safety; Sirolimus; Stents; Survival Analysis; Ticlopidine; Treatment Outcome | 2004 |
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Double-Blind Method; Drug Implants; Female; Humans; Life Tables; Male; Middle Aged; Myocardial Infarction; Premedication; Sirolimus; Stents; Survival Analysis; Ticlopidine; Treatment Outcome; Ultrasonography | 2004 |
Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries.
Topics: Aged; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Complications; Double-Blind Method; Drug Implants; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin; Humans; Incidence; Male; Middle Aged; Randomized Controlled Trials as Topic; Sirolimus; Stents; Ticlopidine; Treatment Outcome | 2004 |
Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy).
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Double-Blind Method; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retreatment; Retrospective Studies; Safety; Sirolimus; Stents; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome | 2007 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, Sudden, Cardiac; Diabetic Angiopathies; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Failure; Reoperation; Sirolimus; Ticlopidine; Treatment Outcome | 2007 |
Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug Delivery Systems; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome; Tunica Intima | 2007 |
Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Sirolimus; Stents; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymers; Product Surveillance, Postmarketing; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Sirolimus; Ticlopidine | 2009 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Risk; Sirolimus; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Europe; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Ischemia; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Sample Size; Single-Blind Method; Sirolimus; Spectroscopy, Near-Infrared; Thiophenes; Tissue Scaffolds; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2012 |
Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.
Topics: Adult; Aspirin; Brazil; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prospective Studies; Research Design; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2012 |
Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.
Topics: Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Follow-Up Studies; Humans; Immunosuppressive Agents; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Registries; Retrospective Studies; Sirolimus; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome; United States | 2013 |
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Retreatment; Sirolimus | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Materials Testing; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Sirolimus | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Sirolimus; Stroke; Thrombosis; Ticlopidine | 2013 |
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Failure; Sirolimus; Ticlopidine; Treatment Outcome | 2014 |
A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine; Treatment Outcome; Tubulin Modulators | 2014 |
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome tria
Topics: Absorbable Implants; Aged; Anti-Inflammatory Agents; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metals; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Polymers; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Sirolimus; Stents; Switzerland; Thiophenes; Treatment Outcome | 2015 |
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Maintenance Chemotherapy; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Failure; Risk Assessment; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Early Termination of Clinical Trials; Europe; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Middle Aged; Middle East; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Treatment Outcome | 2015 |
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Combinations; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Sirolimus; Ticagrelor; Time; Treatment Outcome; Young Adult | 2016 |
Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial.
Topics: Absorbable Implants; Aged; Antibiotics, Antineoplastic; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Ticlopidine | 2016 |
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Risk Factors; Sirolimus; Ticlopidine; Time Factors | 2017 |
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sirolimus; Tetrazoles; Ticlopidine; Treatment Outcome | 2017 |
Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Republic of Korea; Sirolimus; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Vascular response to biolimus A-9 eluting stent in patients with shorter and prolonged dual antiplatelet therapy: optical coherence tomography sub-study of the NIPPON trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyridines; Retrospective Studies; Single-Blind Method; Sirolimus; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Resistance | 2018 |
Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Immunosuppressive Agents; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Design; Receptors, Purinergic P2Y12; Research Design; Risk; Single-Blind Method; Sirolimus; Stents; Thrombosis | 2019 |
Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial.
Topics: Absorbable Implants; Aspirin; China; Clinical Trials, Phase IV as Topic; Coronary Angiography; Coronary Stenosis; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Equivalence Trials as Topic; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Sirolimus; Thrombosis | 2019 |
Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Heart Disease Risk Factors; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Assessment; Sirolimus; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sirolimus; Ticlopidine | 2020 |
Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
Topics: Aged; Aspirin; Biodegradable Plastics; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Humans; Immunosuppressive Agents; Male; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Sirolimus | 2021 |
82 other study(ies) available for aspirin and sirolimus
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs.
Topics: Adenosine; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chymases; Cyclosporine; Diclofenac; Histamine Release; Humans; Immunoglobulin E; Immunosuppressive Agents; Leukotriene C4; Mast Cells; Methotrexate; Middle Aged; Polyenes; Prostaglandins D; Rheumatic Diseases; Serine Endopeptidases; Sirolimus; Substance P; Sulfonamides; Synovial Membrane; Tacrolimus; Tryptases | 1997 |
Oral everolimus inhibits in-stent neointimal growth.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Vessel Prosthesis Implantation; Cell Division; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Endothelium, Vascular; Everolimus; Graft Occlusion, Vascular; Iliac Artery; Immunosuppressive Agents; Muscle, Smooth, Vascular; Rabbits; Sirolimus; Stents; Treatment Outcome; Tunica Intima; Vascular Patency | 2002 |
Very late thrombosis after implantation of sirolimus eluting stent.
Topics: Adult; Aspirin; Blood Vessel Prosthesis; Catheterization; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Drug Implants; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Prosthesis Failure; Retreatment; Sirolimus; Stents; Ticlopidine; Time Factors | 2005 |
Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs.
Topics: Alloys; Angioplasty, Balloon, Coronary; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Carotid Arteries; Clopidogrel; Coronary Angiography; Coronary Restenosis; Disease Models, Animal; Male; Polymers; Sirolimus; Stents; Swine; Ticlopidine; Time Factors; Ultrasonics | 2006 |
Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Immunosuppressive Agents; Liver Transplantation; Middle Aged; Remission Induction; Sirolimus; Telangiectasia, Hereditary Hemorrhagic | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Disease; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Implants; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Internet; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Registries; Risk Factors; Sirolimus; Stents; Thrombosis; Ticlopidine; United States | 2006 |
Percutaneous stenting of the left main with drug eluting stents for in-stent restenosis: immediate- and long-term results.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Domperidone; Humans; Immunosuppressive Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Sirolimus; Stents; Time Factors | 2006 |
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immunosuppressive Agents; Incidence; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Sirolimus; Stents; Ticlopidine; Time Factors | 2006 |
Premature discontinuation of antiplatelet therapy in patients with drug-eluting coronary stents.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Vessels; Delayed-Action Preparations; Humans; Paclitaxel; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Sirolimus; Stents; Ticlopidine | 2006 |
A current problem in cardiology: very late thrombosis after implantation of sirolimus eluting stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Sirolimus; Ticlopidine; Time Factors | 2007 |
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Sirolimus; Stents; Ticlopidine; Tomography, Optical Coherence; Tunica Intima | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Death, Sudden, Cardiac; Drug Implants; Drug Utilization; Endothelium, Vascular; Equipment Design; Equipment Failure; Female; Follow-Up Studies; Humans; Hyperplasia; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine; Tunica Intima; Wound Healing | 2007 |
Clopidogrel and long-term outcomes after drug-eluting stent implantation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Humans; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine | 2007 |
Clopidogrel and long-term outcomes after drug-eluting stent implantation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Humans; Paclitaxel; Platelet Aggregation Inhibitors; Risk Assessment; Sirolimus; Stents; Ticlopidine | 2007 |
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Equipment Design; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Paclitaxel; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Stents; Surface Properties; Ticlopidine; Treatment Outcome | 2007 |
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Diabetes Mellitus; Drug Implants; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Renal Insufficiency; Risk Factors; Sirolimus; Stents; Ticlopidine; Treatment Outcome | 2007 |
Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Delivery Systems; Humans; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine; Time Factors | 2007 |
The influence of low (81 mg) versus high (325 mg) doses of ASA on the incidence of sirolimus-eluting stent thrombosis.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coated Materials, Biocompatible; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Care; Retrospective Studies; Sirolimus; Stents; Treatment Outcome | 2007 |
Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Pyridines; Sirolimus; Stents; Thrombosis; Treatment Outcome | 2007 |
Drug-eluting stents: dual antiplatelet therapy for every survivor?
Topics: Algorithms; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Incidence; Paclitaxel; Platelet Aggregation Inhibitors; Pyridines; Sirolimus; Stents; Survivors; Thrombosis; Ticlopidine | 2007 |
Late stent thrombosis in patients receiving ticlopidine and aspirin after sirolimus-eluting stent implantation.
Topics: Aged; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions.
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort Studies; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Paclitaxel; Polymers; Probability; Prognosis; Reference Values; Risk Assessment; Severity of Illness Index; Sirolimus; Survival Analysis; Treatment Outcome; Vascular Patency; Vasodilator Agents | 2008 |
Very very late thrombosis of a sirolimus-eluting stent: does suboptimal stent expansion take its toll even after three years?
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Radiography; Reoperation; Sirolimus; Ticlopidine; Time Factors | 2008 |
Simultaneous subacute coronary drug-eluting stent thrombosis in two different vessels of a patient with factor V Leiden mutation.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug-Eluting Stents; Factor V; Humans; Male; Middle Aged; Mutation; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Ticlopidine; Warfarin | 2008 |
[Coronary artery bypass grafting for simultaneous subacute stent thrombosis after sirolimus-eluting stent implantation].
Topics: Aged, 80 and over; Angina Pectoris; Aspirin; Coronary Artery Bypass; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Emergencies; Humans; Male; Platelet Aggregation Inhibitors; Sirolimus; Treatment Outcome | 2008 |
Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents.
Topics: Absorption; Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Female; Humans; Lactic Acid; Male; Middle Aged; Platelet Aggregation Inhibitors; Polyesters; Polymers; Sirolimus; Ultrasonography, Interventional | 2008 |
Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Feasibility Studies; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Sirolimus; Ticlopidine | 2008 |
Long-term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Sirolimus; Thrombosis | 2008 |
Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Confidence Intervals; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Immunosuppressive Agents; Incidence; Italy; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Platelet Aggregation Inhibitors; Prospective Studies; Pyridines; Risk Factors; Sirolimus; Time Factors | 2008 |
Status of drug-eluting coronary stents.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Consensus; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Humans; Immunosuppressive Agents; Paclitaxel; Platelet Aggregation Inhibitors; Pyridines; Sirolimus | 2008 |
Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Occlusion; Coronary Stenosis; Coronary Thrombosis; Drug-Eluting Stents; Electrocardiography; Fatal Outcome; Humans; Immunosuppressive Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Sirolimus; Tetrazoles; Ticlopidine; Ventricular Fibrillation | 2010 |
Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents.
Topics: Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Sirolimus; Ticlopidine; Treatment Outcome | 2009 |
Assessment of sirolimus-eluting coronary stent implantation with aspirin plus low dose ticlopidine administration: one year results from CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS).
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Registries; Sirolimus; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2009 |
Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Artery Disease; Databases as Topic; Drug Administration Schedule; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Durapatite; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Prosthesis Design; Registries; Sirolimus; Stainless Steel; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Durapatite; Hyperplasia; Lipids; Materials Testing; Models, Animal; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Stainless Steel; Surface Properties; Sus scrofa; Ticlopidine; Wound Healing | 2009 |
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Polymers; Prosthesis Design; Risk Assessment; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Durapatite; Female; Humans; Intensive Care Units; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Sirolimus; Ticlopidine; Time Factors; Ultrasonography | 2009 |
Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Immunosuppressive Agents; Japan; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Tomography, Optical Coherence; Ultrasonography, Interventional | 2009 |
Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation.
Topics: Aspirin; Cellular Senescence; Cilostazol; Clopidogrel; Down-Regulation; Drug-Eluting Stents; Endothelium, Vascular; Everolimus; Humans; Immunosuppressive Agents; Nitric Oxide Synthase Type III; Oxidative Stress; Paclitaxel; Plasminogen Activator Inhibitor 1; Platelet Aggregation Inhibitors; Sirolimus; Sirtuin 1; Sirtuins; Tetrazoles; Ticlopidine; Vasodilator Agents | 2009 |
Rapamycin enhances platelet aggregation induced by adenosine diphosphate in vitro.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Drug Synergism; Drug-Eluting Stents; Platelet Aggregation; Rabbits; Sirolimus | 2009 |
Triple antiplatelet therapy for clopidogrel resistance with stent malapposition: a case report.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Sirolimus; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Creatinine; Diabetes Mellitus; Drug-Eluting Stents; Follow-Up Studies; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Sirolimus; Stroke Volume; Ticlopidine | 2010 |
Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Ticlopidine; Time Factors | 2011 |
Late and very late stent thrombosis after polymer-based sirolimus- or paclitaxel-eluting stent implantation in real-world clinical practice.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug-Eluting Stents; Humans; Paclitaxel; Platelet Aggregation Inhibitors; Polymers; Sirolimus; Ticlopidine | 2010 |
Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Stenosis; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Registries; Republic of Korea; Risk Assessment; Risk Factors; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Japan; Myocardial Infarction; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Sirolimus; Survival Analysis; Thrombophilia; Ticlopidine; Treatment Outcome | 2011 |
Zymosan suppresses leukotriene C₄ synthase activity in differentiating monocytes: antagonism by aspirin and protein kinase inhibitors.
Topics: Aspirin; Cell Differentiation; Cell Line; Cyclic AMP-Dependent Protein Kinases; Dinoprostone; Glutathione Transferase; Humans; Leukotriene C4; Macrophages; Protein Kinase C; Protein Kinase Inhibitors; Receptors, Prostaglandin E; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Staurosporine; Toll-Like Receptor 2; Zymosan | 2011 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence Intervals; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Risk Reduction Behavior; Sirolimus; Ticlopidine; Time Factors | 2010 |
A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Drug-Eluting Stents; Female; Genotype; Humans; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prosthesis Design; Sirolimus; Thrombectomy; Thrombosis; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Comparison of drug-eluting versus bare metal stents in cardiac allograft vasculopathy.
Topics: Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Disease; Drug-Eluting Stents; Female; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Metals; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Sirolimus; Stents; Ticlopidine; Transplantation, Homologous; Treatment Outcome; Tubulin Modulators | 2011 |
Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Sirolimus; Statistics as Topic; Ticlopidine | 2011 |
Three-year clinical outcome with the Endeavor™ zotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: the Endeavor™ primary PCI study (E-PPCI).
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Confidence Intervals; Drug-Eluting Stents; Female; Heparin; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome; United Kingdom | 2011 |
Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents.
Topics: Antineoplastic Agents, Phytogenic; Aspirin; Belgium; Confidence Intervals; Coronary Restenosis; Drug-Eluting Stents; Female; France; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Platelet Aggregation Inhibitors; Risk Assessment; Sirolimus; Thienopyridines; Time Factors; Treatment Outcome; United States | 2011 |
Medium to long-term clinical outcomes with everolimus-eluting stents in real-life percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; New Zealand; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Sirolimus; Survival Analysis; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
When coronary angiography is not enough to detect spontaneous left main coronary artery dissection.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aortic Dissection; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Metoprolol; Platelet Aggregation Inhibitors; Risk Factors; Sirolimus; Smoking; Ticlopidine; Treatment Outcome | 2012 |
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Dual antiplatelet therapy after drug-eluting stent implantation: is it time to slacken the reins?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Drug-Eluting Stents; Female; Humans; Male; Medication Adherence; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Sirolimus; Ticlopidine; Withholding Treatment | 2012 |
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Disease-Free Survival; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling.
Topics: Adaptor Proteins, Signal Transducing; Aspirin; Ataxia Telangiectasia Mutated Proteins; Berberine; Cell Cycle Proteins; Cell Line, Tumor; Cellular Senescence; Cholecalciferol; Deoxyglucose; DNA Damage; DNA-Binding Proteins; Down-Regulation; Enzyme Activation; Flow Cytometry; Histones; Humans; Laser Scanning Cytometry; Membrane Potential, Mitochondrial; Metformin; Mitochondria; Oxidative Stress; Phosphoproteins; Phosphorylation; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Resveratrol; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Stilbenes; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Simultaneous two-vessel very-late stent thrombosis of everolimus-eluting stents.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug-Eluting Stents; Electrocardiography; Everolimus; Humans; Male; Myocardial Infarction; Patient Compliance; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sirolimus; Treatment Outcome | 2013 |
Quantitative assessment of late lumen loss after biodegradable polymer and permanent polymer sirolimus-eluting stents implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Polymers; Regression Analysis; Sirolimus; Ticlopidine | 2013 |
Consideration of dual anti-platelet therapy duration after drug-eluting stent implantation in a Japanese population: a five-year follow-up after sirolimus-eluting stent implantation.
Topics: Aged; Asian People; Aspirin; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Population Surveillance; Prospective Studies; Pyridines; Retrospective Studies; Sirolimus; Time Factors; Treatment Outcome | 2013 |
"Very" very late stent thrombosis: acute myocardial infarction from drug-eluting stent thrombosis more than 5 years after implantation.
Topics: Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Retrospective Studies; Risk Factors; Sirolimus; Thrombosis; Time Factors | 2014 |
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Prosthesis Design; Sirolimus; Ticlopidine; Treatment Outcome | 2015 |
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Prosthesis Design; Registries; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Thrombosis; Ticlopidine; Treatment Outcome; Young Adult | 2015 |
Accuracy of optical frequency domain imaging for evaluation of coronary adventitial vasa vasorum formation after stent implantation in pigs and humans - a validation study - .
Topics: Adventitia; Aged; Aged, 80 and over; Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Disease Progression; Drug-Eluting Stents; Everolimus; Female; Humans; Interferometry; Male; Middle Aged; Neointima; Neovascularization, Physiologic; Platelet Aggregation Inhibitors; Postoperative Period; Prosthesis Implantation; Sirolimus; Stents; Swine; Swine, Miniature; Ticlopidine; Tomography, Optical Coherence; Vasa Vasorum; Vasculitis | 2015 |
Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Thrombosis; Ticlopidine; Tomography, Optical Coherence | 2016 |
Additive effects of rapamycin and aspirin on dendritic cell allostimulatory capacity.
Topics: Animals; Aspirin; CD40 Antigens; Dendritic Cells; Male; Mice; Mice, Inbred BALB C; Sirolimus; Th1 Cells; Th17 Cells | 2015 |
It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Registries; Sirolimus; Tetrazoles; Thrombosis; Ticlopidine; Treatment Outcome | 2015 |
Synergistic effect of anti-platelet and anti-inflammation of drug-coated Co-Cr substrates for prevention of initial in-stent restenosis.
Topics: Anti-Inflammatory Agents; Aspirin; Cells, Cultured; Chromium Alloys; Cobalt; Coronary Restenosis; Drug Liberation; Drug Synergism; Drug-Eluting Stents; Humans; Microscopy, Electron, Scanning; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Polyesters; Prasugrel Hydrochloride; Propolis; Sirolimus | 2016 |
Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Prospective Studies; Risk Factors; Sirolimus; Treatment Outcome | 2016 |
Early endothelialization associated with a biolimus A9 bioresorbable polymer stent in a porcine coronary model.
Topics: Absorbable Implants; Animals; Aspirin; Coronary Stenosis; Coronary Vessels; Drug-Eluting Stents; Endothelium, Vascular; Humans; Metals; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Swine | 2017 |
Impact of Dual Antiplatelet Therapy Beyond 1 Year on Clinical Outcomes of Patients With Stent Fracture or Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation.
Topics: Aged; Aspirin; Death; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prosthesis Implantation; Pyridines; Retrospective Studies; Sirolimus; Staining and Labeling; Thrombosis; Time Factors; Treatment Outcome | 2017 |
Management of Refractory Pediatric Kaposiform Hemangioendothelioma With Sirolimus and Aspirin.
Topics: Aspirin; Child; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Male; Sarcoma, Kaposi; Sirolimus | 2018 |
Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Japan; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sirolimus; Thrombosis; Tomography, Optical Coherence | 2018 |
Autophagy assuages myocardial infarction through Nrf2 signaling activation-mediated reactive oxygen species clear.
Topics: Animals; Apoptosis; Aspirin; Autophagy; Autophagy-Related Proteins; Disease Models, Animal; Male; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocytes, Cardiac; NF-E2-Related Factor 2; Reactive Oxygen Species; Signal Transduction; Sirolimus | 2020 |
1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y
Topics: Absorbable Implants; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Sirolimus; Stroke; Thrombosis; Treatment Outcome | 2020 |